Results 41 to 50 of about 470,350 (340)

Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group [PDF]

, 2019
Purpose: Many different treatments are suggested by guidelines to treat grade 1−2 (G1−G2) neuroendocrine tumors (NET). However, a precise therapeutic algorithm has not yet been established.
Badalamenti, G., Bianco, A., Colao, A., De Divitiis, C., Di Maio, S., Di Sarno, A., Dolce, P., Faggiano, A., Guarnotta, V., Leo, S., Mocerino, C., Modica, R., Ottaviano, M., Palmieri, G., Puliafito, I., Riccardi, F., Tafuto, S., Tozzi, L.   +17 more
core   +1 more source

A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal

Modern Pathology, 2018
The classification of neuroendocrine neoplasms (NENs) differs between organ systems and currently causes considerable confusion. A uniform classification framework for NENs at any anatomical location may reduce inconsistencies and contradictions among ...
G. Rindi, D. Klimstra, B. Abedi-Ardekani, S. Asa, F. Bosman, E. Brambilla, K. Busam, R. D. de Krijger, M. Dietel, A. El-Naggar, L. Fernandez-Cuesta, G. Klöppel, W. McCluggage, H. Moch, H. Ohgaki, E. Rakha, N. Reed, B. Rous, H. Sasano, A. Scarpa, J. Scoazec, W. Travis, G. Tallini, J. Trouillas, J. V. van Krieken, Ian A. Cree   +25 more
semanticscholar   +1 more source

Delays and routes to diagnosis of neuroendocrine tumours

BMC Cancer, 2018
Background Neuroendocrine tumours are uncommon tumours; there is often a long period between the onset of symptoms and diagnosis. This study aims to address the symptoms prior to diagnosis of people with known neuroendocrine tumours and also the ...
Ron Basuroy, Catherine Bouvier, John Keith Ramage, Maia Sissons, Raj Srirajaskanthan   +4 more
doaj   +1 more source

Sprouting Angiogenesis in Human Pituitary Adenomas

Frontiers in Oncology, 2022
IntroductionAngiogenesis in pituitary tumors is not fully understood, and a better understanding could help inform new pharmacologic therapies, particularly for aggressive pituitary tumors.Materials and Methods219 human pituitary tumors and 12 normal ...
Jie Zhou, Yaomin Hu, Wende Zhu, Chuansheng Nie, Wenxiu Zhao, Alexander T. Faje, Kay E. Labelle, Brooke Swearingen, Hang Lee, E. Tessa Hedley-Whyte, Xun Zhang, Pamela S. Jones, Karen K. Miller, Anne Klibanski, Yunli Zhou, Roy J. Soberman   +15 more
doaj   +1 more source

An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. [PDF]

, 2013
BACKGROUND: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are heterogeneous with respect to biological behaviour and prognosis. As angiogenesis is a renowned pathogenic hallmark as well as a therapeutic target, we aimed to investigate the ...
A Couvelard, A Giatromanolaki, A Rinke, AM Marion-Audibert, AT Dimou, B Terris, D Hanahan, D J Pinato, D O’Toole, DC Metz, DJ Pinato, DJ Pinato, E Raymond, EP Hui, F Panzuto, G Kloppel, HS Kim, I Albrecht, IM Modlin, J LeCouter, J Strosberg, J Zhang, JC Yao, JT Chi, JY Scoazec, K Hirabayashi, K Meeran, K Villaume, M Dal Monte, M Perigny, M Ruscica, MA Maynard, N Martin, N Ngo, P Kuiper, R Dina, R Katoh, R Mentlein, R Ramachandran, R Sharma, S Ezziddin, S T K Toussi, T M Tan, VD Corleto, Y Arvidsson, Y Seo, Y Takahashi, YC Patel   +47 more
core   +2 more sources

The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors

Pancreas, 2020
This manuscript is the result of the North American Neuroendocrine Tumor Society consensus conference on the surgical management of pancreatic neuroendocrine tumors from July 19 to 20, 2018.
J. Howe, N. Merchant, C. Conrad, X. Keutgen, J. Hallet, J. Drebin, R. Minter, T. Lairmore, J. Tseng, H. Zeh, S. Libutti, Gagandeep Singh, Jeffrey E. Lee, T. Hope, M. Kim, Y. Menda, T. Halfdanarson, J. Chan, R. Pommier   +18 more
semanticscholar   +1 more source

Insulinoma: a quarter century of dietary control

Endocrinology, Diabetes & Metabolism Case Reports, 2022
Insulinomas are rare pancreatic neuroendocrine neoplasms (NENs) that are typically sporadic and solitary, with the majority being
Hessa Boharoon, Shaunak Navalkissoor, Tu Vinh Luong, Martyn Caplin, Ashley Grossman   +4 more
doaj   +1 more source

Prenatal exposure to bisphenol A and/or diethylhexyl phthalate alters stress responses in rat offspring in a sex- and dose-dependent manner

Frontiers in Toxicology, 2023
Background: Prenatal exposures to endocrine disrupting chemicals (EDCs) are correlated with adverse behavioral outcomes, but the effects of combinations of these chemicals are unclear.
Amrita Kaimal, Amrita Kaimal, Jessica M. Hooversmith, Ariana D. Cherry, Jillian T. Garrity, Maryam H. Al Mansi, Nicholas M. Martin, Hannah Buechter, Philip V. Holmes, Philip V. Holmes, Puliyur S. MohanKumar, Puliyur S. MohanKumar, Sheba M. J. MohanKumar, Sheba M. J. MohanKumar   +13 more
doaj   +1 more source

The Role of the Brain in the Pathogenesis and Physiology of Polycystic Ovary Syndrome (PCOS). [PDF]

, 2019
Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disorder, affecting at least 10% of women of reproductive age. PCOS is typically characterized by the presence of at least two of the three cardinal features of hyperandrogenemia (high ...
Coutinho, Eulalia A, Kauffman, Alexander S   +1 more
core   +1 more source

The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas

Frontiers in Endocrinology, 2021
Human pituitary adenomas are one of the most common intracranial neoplasms. Although most of these tumors are benign and can be treated medically or by transsphenoidal surgery, a subset of these tumors are fast-growing, aggressive, recur, and remain a ...
Zhiyu Xi, Pamela S. Jones, Masaaki Mikamoto, Xiaobin Jiang, Alexander T. Faje, Chuansheng Nie, Kathryn E. Labelle, Yunli Zhou, Karen K. Miller, Roy J. Soberman, Xun Zhang   +10 more
doaj   +1 more source